BioDelivery Sciences to Participate at the Wells Fargo Securities 2015 Healthcare Conference and the FBR Second Annual Healthcare Conference
RALEIGH, N.C., Sept. 3, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the Company will participate at two upcoming healthcare conferences:
Wells Fargo Securities Healthcare Conference
Date: Wednesday, September 9
Location: Hyatt Regency, Boston, MA
Presentation Time: 9:25 AM Eastern Time
FBR Second Annual Healthcare Conference
Date: Wednesday, September 9
Location: Four Seasons, Boston, MA
No presentation, investor meetings only
At the Wells Fargo Securities Healthcare Conference, Dr. Sirgo will be discussing progress with BDSI's commercial launch of BUNAVAIL® (buprenorphine and naloxone buccal film) and BELBUCA™ (Buprenorphine HCL buccal film), which is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA date of October 23, 2015 for use in patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. Dr. Sirgo will also provide an update on the status of Clonidine Topical Gel being studied for the treatment of painful diabetic neuropathy and Buprenorphine Depot Injection, which is being developed for both chronic pain and opioid dependence.
The Wells Fargo presentation will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. BDSI's headquarters is located in Raleigh, North Carolina.
For more information, please visit or follow us:
Cautionary Note on Forward-Looking Statements
This press release, the presentations described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the presentations described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the commercial launch of BUNAVAIL and the Company's clinical trials for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc All other trademarks and tradenames are owned by their respective owners.
© 2015 BioDelivery Sciences International, Inc. All rights reserved.
SOURCE BioDelivery Sciences International, Inc.
For further information: Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, LLC, 212-915-0685, firstname.lastname@example.org ; Al Medwar, Vice President, Marketing and Corporate Development, BioDelivery Sciences International, Inc., 919-582-9050, email@example.com; Media: Susan Forman/Laura Radocaj, Dian Griesel Int'l., 212-825-3210, firstname.lastname@example.org, email@example.com